Protecting patients during a shortage of thrombolytic agents.

Ní Áinle, Fionnuala; Middeldorp, Saskia; Le Gal, Grégoire; Hunt, Beverley J

Ní Áinle, Fionnuala; Middeldorp, Saskia; Le Gal, Grégoire; Hunt, Beverley J.

Afiliación

Ní Áinle F; School of Medicine, University College Dublin, Dublin D07 AX57, Ireland; Department of Haematology, Mater Misericordiae University Hospital, Dublin, Ireland. Electronic address: fniainle@mater.ie.
Middeldorp S; Department of Internal Medicine, Radboud University Medical Centre, Nijmegen, Netherlands.
Le Gal G; Department of Medicine, University of Ottawa, Ottawa, Canada.
Hunt BJ; Thrombosis and Haemophilia Centre, Guy's and St Thomas' NHS Foundation Trust, London, UK; World Thrombosis Day Campaign, King's Healthcare Partners, London, UK.

Lancet ; 400(10359): 1193-1194, 2022 10 08.

Article en En | MEDLINE | ID: mdl-36216000

Asunto(s)

Fibrinolíticos; Infarto del Miocardio; Fibrinolíticos/uso terapéutico; Humanos; Infarto del Miocardio/tratamiento farmacológico; Terapia Trombolítica

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fibrinolíticos / Infarto del Miocardio Límite: Humans Idioma: En Revista: Lancet Año: 2022 Tipo del documento: Article

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google